175 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Livelsberger Financial Advisory

Livelsberger Financial Advisory purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 175 shares of the medical research company’s stock, valued at approximately $50,000.

Several other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock worth $13,178,910,000 after buying an additional 165,636 shares during the period. Northern Trust Corp increased its holdings in Amgen by 3.8% during the 3rd quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock worth $1,875,306,000 after purchasing an additional 255,463 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Amgen by 3.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,564,710 shares of the medical research company’s stock worth $1,890,769,000 after purchasing an additional 243,720 shares in the last quarter. Royal Bank of Canada grew its holdings in shares of Amgen by 14.8% in the fourth quarter. Royal Bank of Canada now owns 5,831,624 shares of the medical research company’s stock valued at $1,679,625,000 after acquiring an additional 751,947 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Amgen in the fourth quarter valued at approximately $1,556,912,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the sale, the senior vice president now owns 9,883 shares in the company, valued at $3,094,268.47. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.69% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Mizuho raised their price objective on Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research note on Thursday, May 9th. Truist Financial reissued a “buy” rating and set a $320.00 price target on shares of Amgen in a research report on Friday, April 12th. TD Cowen dropped their price target on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. BMO Capital Markets lifted their target price on shares of Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Finally, Raymond James initiated coverage on shares of Amgen in a report on Thursday, March 28th. They issued a “market perform” rating on the stock. Ten research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and a consensus target price of $305.85.

Amgen Trading Up 1.6 %

AMGN opened at $303.28 on Tuesday. The firm has a market capitalization of $162.69 billion, a P/E ratio of 43.33, a P/E/G ratio of 2.70 and a beta of 0.60. The firm’s 50 day moving average is $293.45 and its 200-day moving average is $289.82. Amgen Inc. has a 52-week low of $218.44 and a 52-week high of $329.72. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. The business had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The business’s revenue was up 22.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.98 earnings per share. Analysts expect that Amgen Inc. will post 19.47 EPS for the current fiscal year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.